he
pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha
has emerged as a major target of basic research and clinical investigation.
This cytokine plays a key role in mediating pathological inflammation, and
excess TNF-alpha production has been directly implicated in a wide variety
of diseases.
UCB filed a BLA with the Food and Drug Administration (FDA) for CIMZIA
in the treatment of Crohn's disease on February 28, 2006 and on April 28,
2006 submitted a Marketing Authorization Application (MAA) to the European
Medicines Agency (EMEA) for the same indication. CIMZIA was approved in
Switzerland for the treatment of Crohn's disease in September 2007.
Preparation for a regulatory submission for CIMZIA in the treatment of RA
is ongoing, with filing planned by the end of 2007.
References
(1) American College of Rheumatology Subcommittee on Rheumatoid Arthritis
Guidelines. Guidelines for the Management of Rheumatoid Arthritis 2002
update. Arthritis & Rheumatism, 2002 Vol. 46, No. 2
(2) Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the
progression of radiologic changes in rheumatoid arthritis: Correlation
of radiographic, clinical and laboratory abnormalities. Arthritis &
Rheumatism, 1971, Vol. 14, No. 6
(3) Stakeholder Insight: Rheumatoid Arthritis, Biologics battle up the
treatment algorithm, Data Monitor, 7 September 2006
(4) Woolf AD & Pfleger B, Burden of major musculoskeletal conditions:
Bulletin of the World Health Organization 2003, 81 (9)
(5) Panayi G What is RA? National Rheumatoid Arthritis Society, June 2006
(6) Hellier, J et al, HLA-DRB1 genes and patients with late onset
rheumatoid arthritis, Annals of Rheumatic Disease, 2001;60:531-533
(7) Firestein G, Rheumatoid Arthritis, ACP Medicine WebMD Publishing,
August 2004
About UCB
UCB, Brussels, Belgium
SOURCE UCB Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related medicine technology :1.
Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD2.
DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux3.
Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)4.
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial5.
Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia6.
New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes7.
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis8.
INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients9.
New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy10.
Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults11.
A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities